从PCOS到PMOS：新命名的中国启示

doi:10.16138/j.1673-6087.2026.03.07

内科理论与实践 ›› 2026, Vol. 21 ›› Issue (03): 246-247.doi: 10.16138/j.1673-6087.2026.03.07

从PCOS到PMOS：新命名的中国启示

庞舒月¹^,², 李舍予¹()

1.四川大学华西医院内分泌代谢科，四川成都　610041
2.四川大学华西临床医学院，四川成都　610041

收稿日期:2026-06-12 修回日期:2026-06-22 出版日期:2026-06-25 发布日期:2026-08-19
通讯作者: 李舍予 E-mail：lisheyu@gmail.com
作者简介:作者贡献/Authors’ Contributions:庞舒月负责文章初稿撰写和修改；李舍予负责文章的构思、修改和审定。
基金资助:
癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项(2025ZD0550604);成都市科学技术局重点研发支撑计划(2025-YF09-00033-SN);四川大学135高端人才项目(ZYYC24001)

From PCOS to PMOS: implications of the new nomenclature for China

PANG Shuyue¹^,², LI Sheyu¹()

Received:2026-06-12 Revised:2026-06-22 Online:2026-06-25 Published:2026-08-19

摘要/Abstract

中图分类号:

R711.75

庞舒月, 李舍予. 从PCOS到PMOS：新命名的中国启示[J]. 内科理论与实践, 2026, 21(03): 246-247.

PANG Shuyue, LI Sheyu. From PCOS to PMOS: implications of the new nomenclature for China[J]. Journal of Internal Medicine Concepts & Practice, 2026, 21(03): 246-247.

参考文献 7

[1]	Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process[J]. Lancet, 2026, 407(10545): 2329-2339. doi: 10.1016/S0140-6736(26)00717-8
[2]	Neven ACH, Forslund M, Ranasinha S, et al. Prevalence of polycystic ovary syndrome: a global and regional systematic review and meta-analysis[J]. Hum Reprod Update, 2026, 32(3): 277-312. doi: 10.1093/humupd/dmaf030
[3]	Yang R, Li Q, Zhou Z, et al. Changes in the prevalence of polycystic ovary syndrome in China over the past decade[J]. Lancet Reg Health West Pac, 2022, 25: 100494. doi: 10.2139/ssrn.4048835
[4]	陈向阳, 黄红梅, 李舍予. 成人肥胖的预防与管理: 从六大关键词看2025年度进展与趋势[J]. 中国全科医学, 2026, 29(20): 2753-2758,2774. doi: 10.1016/j.rbmo.2025.105239
	Chen XY, Huang HM, Li SY. Prevention and management of adult obesity: progress and trends from six keywords in 2025[J]. Chin Gen Pract, 2026, 29(20): 2753-2758,2774. doi: 10.1016/j.rbmo.2025.105239
[5]	刘才琪, 王静, 杨海明, 等. 治疗路径理论视角下多囊卵巢综合征患者就医延迟现象的质性研究[J]. 中华现代护理杂志, 2024, 30(32): 4393-4398. doi: 10.3760/cma.j.cn115682-20240304-01106
	Liu CQ, Wang J, Yang HM, et al. Qualitative study on delayed medical treatment in patients with polycystic ovary syndrome from the perspective of treatment pathway theory[J]. Chin J Mod Nurs, 2024, 30(32): 4393-4398. doi: 10.3760/cma.j.cn115682-20240304-01106
[6]	多囊卵巢综合征诊治路径专家共识编写组. 多囊卵巢综合征诊治路径专家共识[J]. 中华生殖与避孕杂志, 2023, 43(4): 337-345.
	Expert Consensus Compilation Group for the Pathway of Diagnosis and Management of Polycystic Ovary Syndrome. Expert consensus on the pathway of diagnosis and management of polycystic ovary syndrome[J]. Chin J Reprod Contracept, 2023, 43(4): 337-345.
[7]	中华医学会外科学分会甲状腺及代谢外科学组, 中国医师协会外科医师分会肥胖和代谢病外科专家工作组, 中国医药教育协会代谢疾病专业委员会, 等. 减重代谢手术治疗肥胖症合并多囊卵巢综合征中国专家共识（2025年版）[J]. 中国普通外科杂志, 2025, 34(2): 183-189. doi: 10.7659/j.issn.1005-6947.250057
	Thyroid and Metabolism Surgery Group of the Chinese Society of Surgery, Chinese Society for Metabolic and Bariatric Surgery, Metabolic Disease Committee of China Medical Education Association, et al. Chinese expert consensus on bariatric metabolic surgery in the treatment of obesity complicated with polycystic ovary syndrome (2025 edition)[J]. Chin J Gen Surg, 2025, 34(2): 183-189. doi: 10.7659/j.issn.1005-6947.250057

从PCOS到PMOS：新命名的中国启示

From PCOS to PMOS: implications of the new nomenclature for China

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 7

相关文章 2

编辑推荐

Metrics

本文评价

[1]	牟睿, 蒋婕, 木卡大斯·热合曼, 童建菁. 绝经后女性衰弱的机制与绝经激素治疗的作用[J]. 内科理论与实践, 2025, 20(06): 505-509.
[2]	曹维, 陈柔柔, 谢媛, 邹婧, 赫荣波, 钱莉, 刘煜. 不同体质量指数多囊卵巢综合征患者内分泌代谢特征的临床研究[J]. 内科理论与实践, 2021, 16(06): 381-386.